tisch.nyu.edu4y
Gene Therapy Research & the Case of Jesse Gelsinger
Seventeen-year-old Jesse Gelsinger had a genetic disease called ornithine transcarbamylase (OTC) deficiency. OTC deficiency prevents the body from breaking down ammonia, a metabolic waste product. In ...
jme.bmj1mon
Harm, ethics committees and the gene therapy death
The recent tragic and widely publicised death of Jesse Gelsinger in a gene therapy trial has ... Jesse was an 18-year-old man with a mild form of ornithine transcarbamylase (OTC) deficiency, a ...
BioWorld14d
Hope in OTC as Iecure’s in vivo gene editing trial shows first response
A 6.5-month-old boy with the rare inherited urea cycle disorder ornithine transcarbamylase (OTC) deficiency has responded positively in a targeted in vivo gene editing trial, in which a correct copy ...
IATP27d
Teen Dies Undergoing Experimental Gene Therapy
Jesse Gelsinger, a high school graduate who had suffered ... Gelsinger suffered from ornithine transcarbamylase (OTC) deficiency, a genetic disorder that affects mostly boys. The disease blocks the ...
Nature10y
Researchers and regulators reflect on first gene therapy death
The Recombinant DNA Advisory Committee (RAC), the National Institutes of Health office responsible for public oversight of gene therapy, met on 8–10 December to examine the clinical trial in ...